Riskpilot← Back to searchSign inGet full accessVELIN-PHARMA A/S
A/SActiveCVR 33026013Kongevejen 66Wholesale of pharmaceutical and medical goods · NACE 4646Est. 1971— employees
Revenue 2025
DKK 95K
-2857% vs 2024
EBITDA margin
100.0%
+2857% vs 2024
Equity ratio
91.0%
Financial strength
Net profit 2025
DKK -16M
-226% vs 2024
| Revenue | DKK 95K | -2857% |
| EBITDA | DKK 95K | +2857% |
| Net profit | DKK -16M | -226% |
| Total assets | DKK 36,8M | -31% |
| Equity | DKK 33,5M | -32% |
| Employees | — | — |
Legal name
VELIN-PHARMA A/S
CVR number
33026013
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
1. februar 1971
Share capital
DKK 700.000
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2025-05-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør alene eller af den samlede bestyrelse
Company purpose
Selskabets formål er at drive handel, fabrikation og finansiering
Address
Kongevejen 66
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 935 | 72 | 299 | 518 | 439 | 164 | 86 | 139 | 279 | 150 | 440 | 161 | -3 | 95 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 935 | 72 | 299 | 518 | 439 | 164 | 86 | 139 | 279 | 150 | 440 | 161 | -3 | 95 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 935 | 72 | 299 | 518 | 439 | 164 | 86 | 139 | 279 | 150 | 440 | 161 | -3 | 95 |
| Net financials | 778 | 1.412 | 2.290 | 1.717 | 991 | -345 | -1.115 | -837 | 3.613 | 7.483 | 3.556 | 7.112 | 16.280 | -16.041 |
| Profit before tax | 1.713 | 1.483 | 2.589 | 2.235 | 1.430 | -181 | -1.030 | -698 | 3.892 | 7.633 | 3.996 | 7.273 | 16.276 | -15.946 |
| Tax | 101 | 395 | 637 | 530 | 323 | -34 | -222 | 300 | 408 | 1.679 | 879 | 1.726 | 3.581 | 75 |
| Net profit | 1.612 | 1.089 | 1.952 | 1.704 | 1.108 | -147 | -807 | -998 | 3.484 | 5.954 | 3.117 | 5.547 | 12.695 | -16.021 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 15.537 | 16.497 | 19.180 | 20.854 | 21.631 | 20.928 | 19.871 | 19.116 | 22.715 | 29.882 | 32.076 | 38.448 | 52.976 | 36.757 |
| Equity | 14.786 | 15.875 | 17.827 | 19.531 | 20.639 | 20.492 | 19.684 | 18.686 | 22.170 | 28.124 | 31.241 | 36.789 | 49.484 | 33.463 |
| Long-term debt | 0 | 0 | 621 | 500 | 277 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 750 | 622 | 732 | 823 | 715 | 437 | 186 | 430 | 545 | 1.758 | 835 | 1.660 | 3.492 | 3.294 |
| Total debt | 750 | 622 | 1.353 | 1.323 | 992 | 437 | 186 | 430 | 545 | 1.758 | 835 | 1.660 | 3.492 | 3.294 |
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
20122025
Equity ratio
91.0%
This company
38.2%
Market median
+138% vs market
20122025
Return on equity
-47.9%
This company
18.4%
Market median
-360% vs market
20122025
Net profit margin
-16870.3%
This company
8.1%
Market median
-208375% vs market
20122025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20122025
Debt / equity
0.10×
This company
0.62×
Market median
+84% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2024-06-01 – 2025-05-31
- Annual report 2024Filed via CVR / Virk · Period 2023-06-01 – 2024-05-31
- Annual report 2023Filed via CVR / Virk · Period 2022-06-01 – 2023-05-31
- Annual report 2022Filed via CVR / Virk · Period 2021-06-01 – 2022-05-31
- Annual report 2021Filed via CVR / Virk · Period 2020-06-01 – 2021-05-31
- Annual report 2020Filed via CVR / Virk · Period 2019-06-01 – 2020-05-31
- Annual report 2019Filed via CVR / Virk · Period 2018-06-01 – 2019-05-31
- Annual report 2018Filed via CVR / Virk · Period 2017-06-01 – 2018-05-31
- Annual report 2017Filed via CVR / Virk · Period 2016-06-01 – 2017-05-31
- Annual report 2016Filed via CVR / Virk · Period 2015-06-01 – 2016-05-31
- Annual report 2015Filed via CVR / Virk · Period 2014-06-01 – 2015-05-31
- Annual report 2014Filed via CVR / Virk · Period 2013-06-01 – 2014-05-31
- Annual report 2013Filed via CVR / Virk · Period 2012-06-01 – 2013-05-31
- Annual report 2012Filed via CVR / Virk · Period 2011-06-01 – 2012-05-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
IH Audit | Audit | 1971 | — | — |
VG Management | Management | 1971 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 1971 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 25.0% | 25.0% | 2002 | |
| Individual | 25.0% | 25.0% | 2002 | |
| Individual | 15.0% | 15.0% | 2002 | |
| Individual | 15.0% | 15.0% | 2002 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of VELIN-PHARMA A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Iver Hansen Iversen | Audit | 0 companies |
| Viggo Gunnar Velin | Management | 0 companies |
| Niels Ebbe Valdal | Board of Directors | 0 companies |